Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push

Merck is set to acquire Cidara Therapeutics for approximately $9.2 billion, or $221.50 per share, in a deal anticipated to close in Q1 2026. The acquisition primarily targets Cidara's lead asset, CD388, a late-stage, strain-agnostic antiviral drug positioned as a single-dose universal preventative for all flu strains, which has demonstrated promising Phase IIb efficacy and is currently in Phase III trials. This transaction highlights Merck's aggressive M&A strategy, representing another significant pipeline expansion this year and ranking among the largest biopharma acquisitions.

Analysis

Merck (MRK) is set to acquire Cidara Therapeutics (CDTX) for approximately $9.2 billion, or $221.50 per share, with the transaction anticipated to close in Q1 2026. This acquisition, approved by both companies' boards, underscores Merck's aggressive M&A strategy, ranking among the top five largest deals of the year and following its $10 billion Verona Pharma buyout. The primary driver for this deal is Cidara's late-stage asset, CD388, a novel, strain-agnostic antiviral drug.

CD388 is positioned as a "single-dose, universal preventative agent" against all flu virus strains, addressing a significant unmet medical need. Phase IIb data demonstrated compelling efficacy, showing 57.7% prevention at a 150mg dose and increasing to 76.1% at a 450mg dose against influenza A and B, with no reported safety issues. This asset is currently in a Phase III trial involving 6,000 high-risk individuals, with an estimated completion in 2027.

This strategic move by Merck highlights a continued trend of large pharmaceutical companies investing heavily in late-stage biotech assets to bolster their pipelines. The strongly positive sentiment surrounding the deal, particularly for Cidara (0.9), reflects the perceived value of CD388's potential in the infectious disease market. Merck's consistent high-value acquisitions, including this one, signal a clear focus on expanding its therapeutic portfolio through external innovation.

Key Decisions for Investors

• Investors should consider the long-term pipeline implications for Merck, particularly the potential market for a universal flu preventative if CD388 successfully completes trials.
• Monitor the progress and outcomes of CD388's ongoing Phase III trial, as its success and market adoption are critical to realizing the acquisition's full value for Merck.
• Evaluate Merck's continued aggressive M&A strategy and its impact on the company's financial leverage and future earnings growth, given multiple large acquisitions this year.